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Background: The prognostic value of circulating tumor cells (CTCs) detected with the CellSearch System in
patients with colorectal cancer (CRC) is controversial. The aim of our meta-analysis was to evaluate whether the
detection of CTCs in the peripheral blood with the standardized CellSearch System has prognostic utility for
patients with CRC.
Methods: The PubMed, Science Citation Index, Cochrane Database, Embase, and the references in relevant studies
were systematically searched (up to December, 2014). No search restrictions were imposed. Our meta-analysis was
performed in Stata software, version 12.0 (2011) (Stata Corp, College Station, TX, USA), with the odds ratio (OR), risk
ratio (RR), hazard ratio (HR), and 95% confidence interval (95% CI) as the effect measures. Subgroup and sensitivity
analyses were also conducted.
Results: Eleven studies containing 1847 patients with CRC were analyzed. There was a significantly higher
incidence of CTCs in the metastasis-positive group than in the metastasis-negative group (OR = 4.06, 95% CI [1.74,
9.50], P < 0.01, I2 = 0%). For hepatic metastasis, a type of metastasis, a higher incidence of CTCs was observed in the
hepatic-metastasis-positive group than in the -negative group (OR = 2.61, 95% CI [1.73, 3.96], P < 0.01, I2 = 0%). The
presence of CTCs was significantly related to overall survival (HR = 2.00, 95% CI [1.49, 2.69], P < 0.01, I2 = 67.1%) and
progression-free survival (HR = 1.80, 95% CI [1.52, 2.13], P < 0.01, I2 = 43.9%) of patients with CRC, regardless of the
sampling time. The response rate for the CTC+ groups was significantly lower than that for the CTC− groups at
baseline and during treatment (baseline: 33% versus 39%, RR = 0.79, 95% CI [0.63, 0.99], P = 0.04, I2 = 7.0%; during
treatment: 17% versus 46%, RR = 0.41, 95% CI [0.22, 0.77], P = 0.01, I2 = 0.0%;).
Conclusions: Our meta-analysis indicates that the detection of CTCs in the peripheral blood with the CellSearch
System has prognostic utility for patients with CRC.
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Colorectal cancer (CRC) is the third most commonly di-
agnosed cancer in males and the second in females
worldwide, with over 1.2 million new cases and 608,700
deaths estimated to have occurred [1]. Recurrence and
metastasis are still the main reasons for CRC-related* Correspondence: josieon826@sina.cn
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unless otherwise stated.deaths, although awareness of CRC has increased and its
treatment improved in recent years [2]. The liver is the
most frequent metastatic site, and metastasis to the liver
can occur through the portal system [3]. However, the
detailed mechanisms of the metastatic cascade of CRC
are yet to be clarified. Today, it is accepted that circulat-
ing tumor cells (CTCs), which are released into the
blood circulation from the primary tumor, play an im-
portant role in the formation of metastases, according to
the “seed and soil theory” [4].This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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in the blood circulation is a poor prognostic indicator
of overall survival (OS) and progression-free survival
(PFS) in patients with CRC [5,6]. In those studies, the
diagnostic methods used to detect CTCs were predom-
inantly reverse transcription–polymerase chain reaction
(RT–PCR) [7] and immunocytochemistry (ICC) [8], tar-
geting either tumor-associated genes or antigens. How-
ever, the detection methods vary across laboratories and
the optimal cut-off value for CTCs has not yet been
confirmed. Currently, the CellSearch System (Veridex,
Raritan, NJ, USA), a semiautomated immunomagnetic
method for the quantification of CTCs based on the
epithelial cell adhesion molecule (EpCAM), is the first
standardized system approved by the U.S. Food and
Drug Administration [9] and has been used to detect
CTCs in patients with breast, prostate, and colorectal
cancer [10-12]. From a clinical perspective, using CTCs
detected in the peripheral blood (PB) to evaluate the
prognosis of cancer is the least invasive procedure for
patients, and is more time effective and repeatable than
assays of the bone marrow or mesenteric/portal blood.
However, for clinical applications, the prognostic utility
of CTCs detected with CellSearch in CRC patients has
not yet been consistently determined [12-15]. Therefore, a
pooled analysis of available studies that have used the Cell-
Search System is required to assess the prognostic rele-
vance of CTC detection in the PB of patients with CRC.
The aim of our study was to use a meta-analysis to
quantitatively and comprehensively summarize the prog-
nostic significance of CTCs detected with the standard-
ized CellSearch System in patients with CRC.
Methods
Search strategy
A literature search for relevant studies was performed
systematically (up to December 2014). The following da-
tabases were searched: PubMed, Science Citation Index,
Cochrane Database, and Embase databases. The refer-
ence lists of the relevant studies (review studies and
included studies) were also checked for potentially rele-
vant articles. The main keywords and MeSH terms used
were: “circulating tumor cells”, “micrometastasis”, “dis-
seminated tumor cells”, “isolated tumor cells”, “occult
tumor cells”, “peripheral blood”, “colorectal cancer”,
“colon cancer”, “rectal cancer”, “gastrointestinal cancer”,
and “CellSearch System” (Additional file 1).
Inclusion criteria
To be included in our meta-analysis, eligible studies had
to fulfill the following criteria: (1) investigated the clini-
copathological or prognostic significance of CTC detec-
tion in CRC patients, with at least one of the outcome
measures of interest reported in the study or calculablefrom the published data; (2) used only the CellSearch
System to detect CTCs; and (3) collected the samples
from the PB. When multiple studies were published by
the same patient population, we included the most in-
formative study.
Exclusion criteria
Studies were excluded from the meta-analysis if: (1) the
samples came from the bone marrow, mesenteric/portal
blood, lymph nodes, or peritoneal cavity; (2) the number
of patients with CRC analyzed in all pooled analyses was
less than 20; (3) the outcomes of interest were not re-
ported or could not be calculated from the original pub-
lished data; and (4) the study was redundant, based on
the same database or patients population as an included
study. To avoid the inclusion of redundant studies, all
the included studies were checked carefully, including
their authors, organizations, the accrual period, and the
population of patients.
Data extraction
Two reviewers (XZ Huang and P Gao) reviewed each of
the studies included, and extracted the data independ-
ently. The following information was collected: first
author, year of publication, country, characteristics of
the study population (i.e., number, sex, age, accrual period,
population), chemoradiotherapy (postoperative or pallia-
tive for inoperable patients), sample time, rate of CTC
positivity, follow-up period, cut-off point, prognostic out-
comes (overall survival [OS] and progression-free survival
[PFS]), hazard ratio (HR), and the objective response to
adjuvant chemotherapy (but not to neoadjuvant chemo-
therapy), according to the Response Evaluation Criteria In
Solid Tumors (RECIST) guideline (complete response
[CR], partial response [PR], stable disease [SD], and pro-
gressive disease [PD]) [16]. Disagreements were resolved
by discussion between the two reviewers.
Assessment of the risk of bias
Two reviewers (XZ Huang and P Gao) used the Newcastle–
Ottawa Scale (NOS) criterion [17], which is used for
nonrandom controlled trials (non-RCTs), to independ-
ently evaluate the quality of the included studies. The re-
sults of quality assessment were confirmed through the
agreement between the two reviewers in the quality as-
sessment. Any disagreements on quality assessment were
resolved via comprehensive discussion. The NOS is
based on three aspects of the study: selection, compar-
ability, and outcome.
Statistical methods and subgroup/sensitivity analysis
Our meta-analysis was completed according to the
recommendations of the Preferred Reporting Items for
Systematic Reviews and Meta-analyses (PRISMA) [18].
Figure 1 Selection of studies. Flow chart showing the selection
process for the including studies.
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by Meta-DiSc (Version 1.4) [19], and the remaining stat-
istical analyses were performed in Stata software, version
12.0 (2011) (Stata Corp, College Station, TX, USA). The
estimated odds ratio (OR) was used to summarize the
association between the detection of CTCs and the clini-
copathological characteristics of CRC. The risk ratio
(RR) and hazard ratio (HR) were used to summarize the
effect measures for the prognostic outcomes (objective
response, PFS, and OS).
If the HR and its variance were not provided directly
by an included study, we calculated these values from
the available data with the method designed by Jayne F
Tierney [20]. By convention, HR, RR, or OR > 1 indi-
cated an unfavorable outcome in the CTC+ group com-
pared with the CTC− group. According to the RECIST
guideline, we assessed the sensitivity and specificity of
CTC+ in predicting objective response to chemotherapy
(no-response events [SD + PD] and disease progression
events [PD]), assuming radiographic imaging to be the
gold standard. In the term of sample time, baseline
defined as the time before the initiation of any first-line
or subsequent systemic chemotherapy, and during-treatment
was defined as the time during the course of systemic
chemotherapy (including first line or subsequent systemic
chemotherapy). All statistical values were reported with
95% confidence intervals (95% CIs) and the two-side
P value threshold for statistical significance was set at
0.05. Heterogeneity among the studies was calculated with
the Q test and I2 statistic [21], and the I2 value indicated
the degree of heterogeneity. A P value <0.10 for the Q
statistic and/or I2 > 50% were considered significant het-
erogeneity, and a random-effects model was used. Other-
wise, a fixed-effects model was used. Meta-regression was
performed to explore the potential variables that contrib-
uted heterogeneity. Besides, Galbraith plot was also used
to explore which study would contribute substantial het-
erogeneity to our meta-analysis.
To retain maximum information, we combined mul-
tiple effect values into a pooled estimate for further ana-
lysis if one study reported several results separately for
different sampling time points. We added additional in-
formation into included study from original authors or
excluded studies if the included and excluded studies
were based on the same patients’ population and some
information of interest was reported in the excluded
studies but not in the included studies. The overall analysis
was completed by enrolling all the relevant studies accord-
ing to the different prognostic outcomes and clinicopatho-
logical parameters. A simultaneous subgroup analysis was
performed based on the sampling time (baseline or during-
treatment). To assess the stability and consistency of our
results and to investigate the impact of single study on re-
sults, sensitivity analyses were conducted by using theleave-one-out approach (omitting each study individually).
Besides, additional subgroup analysis for cut-off values also
was conducted. Publication bias was assessed by Egger’s
and Begg’s tests [22,23].
Results
Baseline characteristics of the included studies
A total of 186 studies were initially identified with the
keywords used to search the databases during a systematic
literature search. By screening the titles and abstracts,
Seventy-five potential studies were retrieved. Sixty-four
studies were then excluded after they were fully reviewed
because they were review (8 studies), irrelevant or lacked
the outcome of interest (51 studies), or redundant (5 stud-
ies). Finally, eleven studies met the inclusion criteria and
were eligible for our meta-analysis (Figure 1).
The eleven studies included contained 1847 patients
with CRC (median sample size: 119 [20–472]; mean: 168)
[13-15,24-31]. The studies were conducted in Asia,
Europe, and North America (Japan, Germany, Denmark,
Spain, France, Netherlands, Norway, Italy and America)
and were published between 2008 and 2014. According to
the sampling time points, six studies only assessed CTCs
at baseline [13,14,25,26,29,30], one study only assessed
CTCs at the during-treatment time point [24], and three
studies assessed CTCs at baseline and during-treatment
time point separately [27,28,31], and one study assessed
CTCs combined at both time points [15]. HRs for OS and
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[14,24-28,30,31] of the studies, respectively. The baseline
characteristics of the included studies and the study design
variables are summarized in Table 1. The quality of the
eight included cohort studies was evaluated according to
NOS and is summarized in Table 2.
Association between the presence of CTCs and tumor
metastasis
Three studies reported the incidence of CTCs in metastasis-
positive and -negative groups [13,15,29]: one study showed
a statistically significant difference between the groups
[13] and two studies showed a worse trend toward metas-
tasis in patients with CTCs [15,29], although the differ-
ences were not statistically significant. A meta-analysis of
all the relevant studies of metastasis showed a significantly
higher incidence of CTCs in the metastasis-positive
groups than in the metastasis-negative groups (OR = 4.06,
95% CI [1.74, 9.50], P < 0.01, I2 = 0%; Figure 2A). We also
conducted a meta-analysis to investigate the association
between hepatic metastasis, which is the most common
type of metastasis in patients with CRC, and the detection
of CTCs. The pooled results showed a significantly higher
incidence of CTCs in the hepatic-metastasis-positive
groups than in the hepatic-metastasis-negative groups
(OR= 2.61, 95% CI [1.73, 3.96], P < 0.01, I2 = 0%; Figure 2B).
Impact of CTCs on survival outcomes (OS and PFS)
The HRs for OS and PFS were available in nine
[14,15,24,25,27-31] and eight [14,24-28,30,31] studies,
respectively. The pooled analysis revealed that the detec-
tion of CTCs with the CellSearch System in patients
with CRC was associated with a worse OS (HR = 2.00,
95% CI [1.49, 2.69], P < 0.01, I2 = 67.1%; Figure 3A) and
a worse PFS (HR = 1.80, 95% CI [1.52, 2.13], P < 0.01,
I2 = 43.9%; Figure 3B). Sensitivity analyses confirmed the
stability of our results, and indicated that our results
were not obviously affected and dominated by any single
study or different cut-off values.
In the subgroup analysis based on sampling time, a
significant prognostic effect of CTC detection was con-
firmed in the analysis of studies that collected the sam-
ples at baseline (OS: HR = 1.78, 95% CI [1.34, 2.37],
P < 0.01, I2 = 54.3%; PFS: HR = 1.55, 95% CI [1.35, 1.77],
P < 0.01, I2 = 4.0%), as well as during-treatment (OS: HR
= 3.02, 95% CI [2. 07, 4.40], P = 0.01, I2 = 61.6%; PFS:
HR = 2.50, 95% CI [2.14, 2.92], P < 0.01, I2 = 0.0%). Four
studies assessed the prognostic value of CTCs at various
cut-off values [24-26,29]. Subgroup analyses based on
cut-off values indicated that CTC+ at cut-off values
of ≥1/7.5 ml (OS: HR = 2.94, 95% CI [0.51-17.01],
P = 0.23; PFS: HR = 1.46, 95% CI [0.92-2.31], P = 0.11)
and ≥2/7.5 ml (OS: HR = 1.67, 95% CI [0.84-3.31],
P = 0.15; PFS: HR = 1.53, 95% CI [0.72-3.25], P = 0.27)tended to have an unfavorable prognosis, although stat-
istical significance was not reached. And the result
for cut-off values of ≥3/7.5 ml (OS: HR = 1.66, 95% CI
[1.14-2.42], P < 0.01; PFS: HR = 1.79, 95% CI [1.52-2.11],
P < 0.01) reached statistical significance.
The results of quality assessment of the included stud-
ies (Table 2) were summarized in Table 2. After exclud-
ing the study with lowest quality (NOS Score = 3) [30],
our results still indicated that CTC+ group was associ-
ated with a worse OS and PFS in patients with CRC
(OS:HR = 2.08, 95% CI [1.57, 2.75, P < 0.01, I2 = 65.6%;
PFS:HR = 1.77, 95% CI [1.48, 2.13, P < 0.01, I2 = 51.7%).
Objective response to adjuvant chemotherapy
Only three studies assessed the correlation between CTCs
and radiographic imaging results in patients receiving adju-
vant chemotherapy [14,31,32]. The pooled results showed
that the response rate for the CTC+ groups was signifi-
cantly lower than that for the CTC− groups at baseline and
during treatment (baseline: 33%, 95% CI [27%, 39%] versus
39%, 95% CI [35%, 44%], RR = 0.79, 95% CI [0.63, 0.99],
P = 0.04, I2 = 7.0%, Figure 4A; during treatment: 17%, 95%
CI [6%, 28%] versus 46%, 95% CI [33%, 59%], RR = 0.41,
95% CI [0.22, 0.77], P = 0.01, I2 = 0.0%, Figure 4B).
When we assumed radiographic imaging to be the
gold-standard diagnostic procedure, the sensitivity for
the baseline CTC+ group in detecting no-response events
(SD + PD) was 37% (95% CI [32%, 42%]) and the specifi-
city was 70% (95% CI [63%, 76%]), and summary diagnos-
tic OR was 1.47 (95% CI [1.03, 2.10]). Sensitivity for
the during-treatment CTC+ group was 13% (95% CI [9%,
17%]) and the specificity was 96% (95% CI [92%, 98%]),
and summary diagnostic OR was 3.89 (95% CI [1.71,
8.88]). For the imaging disease progression events (PD),
sensitivity and specificity for the baseline CTC+ group
were 26% (95% CI [14%, 40%]) and 70% (95% CI [65%,
75%]), and summary diagnostic OR was 0.75 (95% CI
[0.34, 1.66]). Sensitivity and specificity for the during-
treatment CTC+ group were 26% (95% CI [17%, 36%])
and 94% (95% CI [92%, 96%]), and summary diagnostic
OR was 4.73 (95% CI [2.56, 8.73]).
Assessment of heterogeneity and publication bias
Our meta-regression suggested that cut-off values, sam-
pling time, sample size and publication year did not
affect the estimated HRs for PFS and OS obviously. The
results of meta-regression may be affected by limited
number of studies. Moreover, Galbraith plot showed that
the study by Sotelo et al. [24] may mainly contribute
substantial heterogeneity to our meta-analysis. Potential
publication bias was evaluated by Begg’s and Egger’s
tests. There was no evidence of publication bias for the
pooled analysis of OS (PBegg = 0.60, PEgger = 0.15) and
PFS (PBegg = 0.90, PEgger = 0.18) (Figure 5).
Table 1 Baseline characteristics and design variables of the including studies
Article Number (M/F)1 C/R/R-S2 Age Mean ± SD3/
Median (range)
ST4 Cut-off Rate(+)5 Follow up Mean ± SD/
Median (range)
OM6 Surgery MA7
Sotelo 2014 [24] 472(254/218) 425/47/0 Median:66(31–87) Baseline ≥1/7.5 ml 166/472 Median:40(NR8) OS9; PFS10 YES NO
472(254/218) 425/47/0 Median:66(31–87) Baseline ≥2/7.5 ml 93/472 Median:40(NR) OS; PFS YES NO
472(254/218) 425/47/0 Median:66(31–87) Baseline ≥3/7.5 ml 57/472 Median:40(NR) OS; PFS YES NO
472(254/218) 425/47/0 Median:66(31–87) Baseline ≥5/7.5 ml 34/472 Median:40(NR) OS; PFS YES NO
Seeberg 2014 [25] 194(105/89) 124/70 Median:65(31–93) Baseline ≥1/7.5 ml 37/189 Median:22.5(1–61) OS; PFS 153YES NO
194(105/89) 124/70 Median:65(31–93) Baseline ≥2/7.5 ml 26/189 Median:22.5(1–61) OS; PFS 153YES YES
194(105/89) 124/70 Median:65(31–93) Baseline ≥3/7.5 ml 17/189 Median:22.5(1–61) OS; PFS 153YES NO
Gazzaniga 2013 [26] 119(68/51) NR Median:64(29–84) Baseline ≥1/7.5 ml 44/119 Median:12(1–26) PFS NR YES
119(68/51) NR Median:64(29–84) Baseline ≥3/7.5 ml 24/119 Median:12(1–26) PFS NR YES
Aggarwal 2013 [27] Baseline:209(NR) NR Mean:63.0 ± 12.6
Median: 64 (22–92)





≥3/7.5 ml 3-5 W: 17/115;
6-12 W: 10/134
NR OS NR YES
Kuboki 2013 [14] 63(34/29) 41/22/0 Median: 61(33–81) Baseline ≥3/7.5 ml 19/63 Median:8.7(NR) OS; PFS NR YES
Deneve 2013 [13] 69(43/26) 66/8/1 Median: 75(38–95) Baseline ≥1/7.5 ml 20/69 Mean:31 ± NR
Median:36 (0–52)
NR YES NO
Sastre 2012 [28] Baseline:180(118/62) 40/121/19 Median: 65(40–82) Baseline ≥3/7.5 ml 85/180 NR OS; PFS 123YES YES
Cycle3:147(NR) NR NR Cycle3 ≥3/7.5 ml 23/147 NR OS; PFS 123YES NO
Sato 2012 [29] 25(NR) NR NR Baseline ≥3/7.5 ml 14/25 NR OS M1:NO12 NO
25(NR) NR NR Baseline ≥1/7.5 ml 18/25 NR OS M1:NO NO
Papavasiliou 2010 [30] 20(13/7) NR Median: 54 (41–81) Baseline
During-treatment
≥3/7.5 ml Pre:2/20 intra:
10/20; post: 1/18
Median:11.5 (5–25) OS; PFS YES NO





NR Median: 63(27–83) During-treatment:
1-2/3-5/6-12/13-20 W




NR OS; PFS NR YES
























Table 2 The assessment of the risk of bias in each Cohort study using the Newcastle-Ottawa scale
Study
Selection (0-4) Comparability(0-2) Outcome (0-3)
Total
REC SNEC AE DO SC AF AO FU AFU
Sotelo 2014 [24] * * * * - - * * - 6
Seeberg 2014 [25] * * * * - - * * * 7
Gazzaniga 2013 [26] - * * * - - * - - 4
Aggarwal 2013 [27] - * * * - - * * - 5
Kuboki 2013 [14] - * * * - - * * - 5
Deneve 2013 [13] - * * * - - * * - 5
Sastre 2012 [28] * * * * - - * * - 6
Sato 2012 [29] * * * * - - * - - 5
Papavasiliou 2010 [30] - - * * - - * - - 3
Tol 2010 [31] * * * * - - * - - 5
Hiraiwa 2008 [15] - * * * - - * - - 4
NOTE. REC: representativeness of the exposed cohort; SNEC: selection of the non-exposed cohort; AE: ascertainment of exposure; DO: demonstration that outcome
of interest was not present at start of study; SC: study controls for age, sex; AF: study controls for any additional factors (chemoradiotherapy, curative resection);
AO: assessment of outcome; FU: follow-up long enough (36M) for outcomes to occur; AFU: adequacy of follow-up of cohorts (≥90%).'*' means that the study is
satisfied the item (high quality with no bias), and '-' means that the study is not satisfied the item (low quality with bias); Total: the number of high-quality items
(no bias) in each study.
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In recent years, the prognosis of patients with CRC has
improved remarkably after resection surgery combined
with chemoradiotherapy [33,34]. However, the problems
of metastasis, recurrence, and resistance to drugs areFigure 2 Odds ratios summary for all kinds of tumor metastasis (A) a
summarized for the relationship between all kinds of tumor metastasis and
between hepatic metastasis and CTC detection.not yet resolved, and the causes and mechanisms of
these phenomena have not been clarified [35]. Since
CTCs were first identified in the PB of patients with
CRC, the detection and study of CTCs have become a
very topical issue for investigators worldwide [10]. And hepatic metastasis (B). A: The estimated odds ratio (OR) was
CTC detection. B: The OR was summarized for the relationship
Figure 3 Hazard ratios summary for overall survival (A) and progression-free survival (B). A: The estimated hazard ratio (HR) was
summarized for overall survival with CTC detection. B: The estimated HR was summarized for progression-free survival with CTC detection.
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the presence of CTCs in the blood circulation of patients
with CRC was an indicator of a poor prognosis [36], but
that meta-analysis was limited by the presence of meth-
odological heterogeneity because the enrolled studies
used several different detection methods and were not
stratified by method. The utility of CTC detection in the
PB with the standardized CellSearch System has been
demonstrated in several studies [37,38]. Deneve et al. re-
ported that CTC detection in PB with the CellSearch
System was convenient and correlates with tumor me-
tastasis and prognosis [13]. However, Hiraiwa et al. and
Kuboki et al. showed that the prognostic effects were
not statistically significant [14,15]. Therefore, the prog-
nostic role of CTC detection in the PB with the Cell-
Search System is still controversial.
This is the first comprehensive meta-analysis to deter-
mine the significance of CTC detection with the Cell-
Search System only. It suggests that patients with CTCs
have poorer OS and PFS than those who lack CTCs, in-
dicating that the clinical prognosis of patients with CRCis significantly associated with the CTCs detected in the
PB with the CellSearch System. The absence of publica-
tion bias was confirmed with funnel plots (Figure 5).
To avoid the influence of temporal heterogeneity, a
subgroup analysis was performed based on sampling
time, and the estimated results for OS and PFS remained
stable and were not markedly affected by sampling time.
Our results indicated that CTCs detected not only at
baseline but also during treatment could be considered a
prognostic factor. These results are consistent with pre-
vious studies by Iinuma et al. and de Albuquerque et al.,
who used RT–PCR methods [7,39]. Uncertainties still
remain about which sampling time (at baseline, during
treatment, or at the completion of systemic treatment)
could provide the most accurate prognostic information.
The present study suggested that the association between
prognosis and CTC detection was more pronounced and
persuasive when the samples were collected during treat-
ment than at baseline. The best explanation for this may
be that the during-treatment CTC status provides rela-
tively more information on survival outcomes than the
Figure 4 Risk ratios summary for the correlation of tumor response and CTCs. A: The estimated risk ratio (RR) was summarized for the
correlation of tumor response with CTCs detected at baseline time. B: The estimated RR was summarized for the correlation of tumor response
with CTCs detected at during-treatment time.
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status combines the baseline CTC status and the tumor
cells release during surgical manipulation [40]. Early-
detected CTCs are not always associated with the survival
outcome, because a portion of the early-detected CTCs
can be inactivated and cleared by chemotherapeutic ef-
fects during chemotherapy, after which they will not affect
the prognosis. Later samples could also contain additional
CTCs that have been released from the primary tumor
after changes in the tumor proliferative activity [41,42].
Therefore, later samples could more accurately reflect the
CTC status by including CTC release, proliferation, apop-
tosis, and necrosis. Our results indicated that during-
treatment sample collection was preferable to baseline
collection in using CTCs to predict CRC outcomes.
Our result also showed a significantly higher incidence
of CTCs in the hepatic-metastasis-positive groups than
in the hepatic-metastasis-negative groups, which was
consistent with a recent meta-analysis by Katsuno et al.
[43] and supported the results of our meta-analysis of
PFS. These results suggested that the liver could act as a
suitable “soil” for CTCs and as an internal filter for
tumor cells, which are shed at high concentrations from
the primary tumor [44,45]. A possible explanation is that
hepatic metastatic foci develop from micrometastatic foci
formed by CTCs via hematogenous metastasis [4,46].
Furthermore, because the CellSearch System detects andquantifies CTCs based on the EpCAM protein on the
CTCs, some investigators consider that EpCAM might
play an important role in hepatic metastasis, cancer stem-
ness, and the epithelial mesenchymal transition [47]. This
hypothesis is supported by several studies that have re-
ported that catumaxomab (anti-EpCAM× anti-CD3 anti-
bodies) shows convincing therapeutic efficacy in patients
with malignant tumors [48,49]. The high expression of the
laminin receptor and the secretion of proteolytic enzymes
by tumor cells also contribute to tumor migration and
invasion [50,51].
Several studies have indicated that the presence of
CTCs could be used to monitor the therapeutic effects
of chemotherapy. In the studies we analyzed, only three
[14,31,32] evaluated the correlation between CTCs and
tumor responses on imaging according to the RECIST
criteria. Our results indicated that CTCs detected at
baseline or during treatment could predict the response
to chemotherapy. Consequently, it might be appropriate
to guide therapeutic decision-making on the basis of
CTC counts, e.g., CTCs in the PB may be useful in iden-
tifying patients who could safely undertake prolonged
treatment breaks from those who should resume therapy
more rapidly [12]. The tailoring of targeted treatments
could also be improved by the molecular analysis of epi-
dermal growth factor receptor (EGFR) or Kirsten rat sar-
coma viral oncogene homolog (KRAS genes) expression
Figure 5 Funnel plot analysis. A: overall survival; B: progression-free survival. A: Funnel plot of the studies on overall survival. B: Funnel
plot of the studies on progression-free survival.
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of resistance to anti-EGFR monoclonal antibodies (i.e.,
cetuximab) [52].
As with other methods, there is no consensus on the
optimal cut-off value for CTCs in the PB for predicting
the prognoses of patients with CRC. Although most
studies used a cut-off value of CTCs ≥3/7.5 ml of blood
and our results indicated that a cut-off value of CTCs
≥3/7.5 was available, an optimal cut-off value defining
CTC positivity in patients with CRC is still not settled
and several studies used various cut-off values to assess
the clinical significance of CTCs [25,26]. The studies by
Seeberg et al. and Gazzaniga et al. showed that cut-off
value of CTCs ≥1/7.5 or ≥2/7.5 ml was also associated
with poor prognosis in patients with CRC [25,26]. More-
over, our subgroup analyses suggested that CTC+ at
cut-off values of CTCs ≥1/7.5 ml and≥≥ 2/7.5 ml
also strongly tended to have an unfavorable prognosis.
Thus, CRC patients with 1–2 CTC may be switched
from the favorable prognostic group to the unfavorable
prognostic group, deserving a more careful monitoring.
Furthermore, it is unclear whether the cut-off values of
CTCs are different between non-metastatic and meta-
static CRC patients, considering the difference of cut-off
values in non-metastatic and metastatic breast cancer
(non-metastatic breast cancer: ≥1/7.5 ml; metastatic
breast cancer: ≥5/7.5 ml) [53,54]. Thus, establishing a
set of optimal cut-off values for CTC detection will re-
quire well-designed, large-scale multicenter studies.
As a semiautomated immunological technique, the
CellSearch System has some obvious advantages relative
to traditional ICC, including its easy operation, time
effectiveness, and better CTC enrichment. Other advan-
tages of the CellSearch System include its higher specifi-
city and reproducibility than those of RT–PCR techniques.
Moreover, CellSearch System could directly label the
CTCs based on EpCAM, identify the viable versus nonvia-
ble CTCs, and visually acquire and quantify the CTCs
[55]. In recent years, the use of the CellSearch System has
been very widespread because it provides the further cyto-
logical analysis possible of CTCs, including the evaluation
of the expression of chemotherapeutic or biologically
therapeutic targets (e.g., EGFR and KRAS) [56].
Although our meta-analysis of studies that have used
the CellSearch System reduced the heterogeneity caused
by including studies based on other detection methods,
there was still a considerable degree of heterogeneity in
our meta-analysis. Specifically, in the pooled analysis
of OS and PFS, heterogeneity was mainly caused by
the study by Sotelo et al.[24]. Heterogeneity may also
result from difference in patient characteristics (i.e.,
age, sex, or race), sampling time, or treatment regimens.
The temporal and phenotypic heterogeneity of CTCs
was also a source of heterogeneity. Differences in theexperimental designs of the cohort studies also gener-
ated nonnegligible heterogeneity.
Several limitations must be addressed. First, as a retro-
spective study, our meta-analysis focused on the sum-
mary of published data from previous studies. Several
studies did not provide HRs and we estimated them
from the reported data. Second, there was considerable
heterogeneity in our study. We addressed this heterogen-
eity by using a random-effects model to obtain more-
conservative estimates if there was heterogeneity significant.
It is well-known that the prognoses of patients with
and without surgery are different. Therefore, most stud-
ies examined these two groups separately. However,
Aggarwal et al., Kuboki et al., Tol et al., and Gazzaniga
et al. did not report whether their patients underwent
surgery [14,26,27,31]. We could not conduct a subgroup
analysis, separating the patients into surgical and nonsur-
gical groups, in our meta-analysis because the number of
studies was limited. The number of studies included
here may have been insufficient to analyze the associ-
ation between CTC detection and hepatic metastasis
and the correlation between CTCs and tumor response
to chemotherapy, which may have affected the internal
and external validity of our results. Despite these limita-
tions, our meta-analysis is the first study to evaluate the
prognostic utility of CTCs detected with the CellSearch
System in CRC patients.
Conclusions
Our meta-analysis suggests that the detection of CTCs
in the PB with the CellSearch System is a prognostic fac-
tor for patients with CRC. Future high-quality, well-
designed multicenter studies are required to assess the
clinical values and clinical utility of CTCs detected by
CellSearch System in colorectal patients.
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